Melphalan/hepatic delivery system showed better survival and response rates than best alternative care in metastatic uveal ...

Roger Li, MD, discusses the MoonRISe-1 study evaluating TAR-210 in FGFR-altered intermediate-risk non-muscle-invasive bladder cancer.

The FDA has approved new agents in ovarian cancer and non–small cell lung cancer and paved the way for novel antibody-drug conjugate developments.